Monopar Therapeutics Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 7 - Net Loss Per Share

Note 7 - Net Loss Per Share

3 Months Ended

Mar. 31, 2025

Notes to Financial Statements

Earnings Per Share [Text Block]

Note 7 – Net Loss Per Share

Basic and diluted net loss per common share was calculated as follows:

	*Three Months Ended March 31,*
(in thousands, except for net loss per share)	*2025*			2024**
Numerator:
Net loss	$	(2,625	)	$	(1,641	)

Denominator:
Weighted-average common shares outstanding, basic and diluted		6,987			3,196

Net loss per common share, basic and diluted	$	(0.38	)	$	(0.51	)

Anti-dilutive potential common stock equivalents excluded from the calculation of net loss per share:
Stock options to purchase common stock		620			424
Unvested restricted stock units		149			73

^**Information pertaining to number of shares outstanding gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024.